Form Type: 4

SEC EDGAR Link
Accession Number:0001415889-23-007688
Date:2023-05-05
Issuer: HALOZYME THERAPEUTICS, INC. (HALO)
Original Submission Date:

Reporting Person:

CONNAUGHTON BERNADETTE
C/O HALOZYME THERAPEUTICS, INC.
12390 EL CAMINO REAL SAN DIEGO, CA 92130

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2023-05-05 A 8,065 a $0.00 40,286 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
OPTION TO PURCHASE COMMON STOCK 31.0 2023-05-05 deemed execution date A 11,371 (a) 2024-05-05 2033-05-05 common stock 11,371 $31.00 11,371 direct
Footnotes
IDfootnote
f1 represents annual restricted stock unit ("rsu") grant under the issuer's director compensation program. each rsu represents the right to receive one share of common stock of the issuer. this grant will vest in full on the earlier of (i) may 5, 2024 and (ii) the date of the issuer's next annual meeting of stockholders. these stock units are subject to a written deferral election under the issuer's directors deferred equity compensation plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
f2 represents annual stock option grant under the issuer's director compensation program. this grant will vest in full on the earlier of (i) may 5, 2024 and (ii) the date of the issuer's next annual meeting of stockholders.
WhaleWisdom Logo

Elevate your investments